Diabetes mellitus: A review on pathophysiology, current status of oral medications and future perspectives

Acta Pharmaceutica Sciencia

Volumn 55, Issue 1, 2017, Pages 61-82

  Okur, Mehmet Evren ^a,b   Karantas, Ioannis D ^c   Siafaka, Panoraia I ^d  

^a ANADOLU UNIVERSITY   (Turkey)

^b Eskisehir State Hospital   (Turkey)

^c Ippokration Hospital Thessaloniki   (Greece)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Current status; Diabetes mellitus; Epidemiology; Medications

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG CARRIER; EMPAGLIFLOZIN; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; METFORMIN; MIGLITOL; OMARIGLIPTIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; UNINDEXED DRUG;

ADD ON THERAPY; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTHRALGIA; DIABETES MELLITUS; DIABETIC FOOT; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STRUCTURE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIVER CANCER; NANOEMULSION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREATITIS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PREGNANCY DIABETES MELLITUS; PREVALENCE; REVIEW; SUSTAINED RELEASE FORMULATION; TABLET FORMULATION; VOMITING;

EID: 85018762400     PISSN: 13072080     EISSN: None     Source Type: Journal    
DOI: 10.23893/1307-2080.APS.0555     Document Type: Review

References (84)

1. World Health Organization. Global Report on Diabetes. 2016, 88.
2. Piero, M. N. Diabetes Mellitus – a Devastating Metabolic Disorder. Asian J. Biomed. Pharm. Sci. 2015, 4 (40), 1–7.
3. Patlak, M. New Weapons to Combat an Ancient Disease: Treating Diabetes. FASEB J. 2002, 16 (14), 1853.
4. Ahmed, A. M. History of Diabetes Mellitus. Saudi Med. J. 2002, 23 (4), 373–378.
5. White Jr. J.R. A Brief History of the Development of Diabetes Medications. Diabetes Spectr. 2014, 27 (2), 82–86.
6. Link, C. L.and McKinlay, J. B. Disparities in the Prevalence of Diabetes: Is It Race/ethnicity or Socioeconomic Status? Results from the Boston Area Community Health (BACH) Survey. Ethn. Dis. 2009, 19 (3), 288–292.
7. Miller, S. T.; Schlundt, D. G.; Larson, C.; Reid, R.; Pichert, J. W.; Hargreaves, M.; Brown, A.; McClellan, L.; Marrs, M. Exploring Ethnic Disparities in Diabetes, Diabetes Care, and Lifestyle Behaviors: The Nashville REACH 2010 Community Baseline Survey. Ethn. Dis. 2004, 14 (3 Suppl 1), S38-45.
8. Heidemann, D. L.; Joseph, N. A.; Kuchipudi, A.; Perkins, D. W.; Drake, S. Racial and Economic Disparities in Diabetes in a Large Primary Care Patient Population. Ethn. Dis. 2016, 26 (1), 85–90.
9. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2010, 33 (Supplement_1), S62–S69.
10. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2013, 36 (Supplement_1), S67–S74.
11. Tan, Y.; Chang, S. K. C.and Zhang, Y. Comparison of α-Amylase, α-Glucosidase and Lipase Inhibitory Activity of the Phenolic Substances in Two Black Legumes of Different Genera. Food Chem. 2017, 214, 259–268.
12. Rossi, E. J.; Sim, L.; Kuntz, D. A.; Hahn, D.; Johnston, B. D.; Ghavami, A.; Szczepina, M. G.; Kumar, N. S.; Sterchi, E. E.; Nichols, B. L.; Pinto, B. M.; Rose, D. R. Inhibition of Recom-binant Human Maltase Glucoamylase by Salacinol and Derivatives. FEBS J. 2006, 273 (12), 2673–2683.
13. http://www.diabetesatlas.org/resources/2015-atlas.html
14. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2014, 37(Supplement_1), S81–S90.
15. Gale, E. The Discovery of Type 1 Diabetes. Diabetes 2001, 50, 217–226.
16. Wu, H.; Walker, J.; Damhuis, R. A.; Brewster, D. H.; Wild, S. H. Metformin and Survival of People with Type 2 Diabetes and Pleural Mesothelioma: A Population-Based Retrospective Cohort Study. Lung Cancer 2016, 99, 194–199.
17. Olokoba, A. B.; Obateru, O. A.and Olokoba, L. B. Type 2 Diabetes Mellitus: A Review of Current Trends. Oman Med. J. 2012, 27 (4), 269–273.
18. Standards of Medical Care in Diabetes--2014. Diabetes Care 2014, 37 (Supplement_1), S14–S80.
19. Standards of Medical Care in Diabetes—2015 Abridged for Primary Care Providers. Clin. Diabetes 2015, 33 (2), 97–111.
20. Milligan, S. Combination Therapy for the Improvement of Long-Term Macrovascular and Microvascular Outcomes in Type 2 Diabetes: Rationale and Evidence for Early Initiation. J. Diabetes Complications 2016, 30 (6), 1177–1185.
21. Inzucchi, S. E.; Bergenstal, R. M.; Buse, J. B.; Diamant, M.; Ferrannini, E.; Nauck, M.; Peters, A. L.; Tsapas, A.; Wender, R.; Matthews, D. R. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015, 38 (1), 140–149.
22. Garber, A. J.; Abrahamson, M. J.; Barzilay, J. I.; Blonde, L.; Bloomgarden, Z. T.; Bush, M. A.; Dagogo-Jack, S.; DeFronzo, R. A.; Einhorn, D.; Fonseca, V. A.; Garber, J. R.; Garvey, W. T.; Grunberger, G.; Handelsman, Y.; Henry, R. R.; Hirsch, I. B.; Jellinger, P. S.; McGill, J. B.; Mechanick, J. I.; Rosenblit, P. D.; Umpierrez, G. E. Consensus statement by the AmericN Association of clinical endocrinologists and American College of Endocrinology on the comprehensive type2 diabetes management algorithm-2016 executive summary. Endocr. Pract. 2016, 22 (1), 84–113.
23. McMillan, T.; Girgis, R.and Sellers, E. A. C. Neonatal Diabetes and Protein Losing Enteropa-thy: A Case Report. BMC Med. Genet. 2016, 17 (1), 32.
24. Chakraborty, P. P.; Ray, S.; Bhattacharjee, R.; Ghosh, S.; Mukhopadhyay, P.; Mukhopadhyay, S.; Chowdhury, S. First Presentation of Diabetes as Diabetic Ketoacidosis in a Case of Friedreich’s Ataxia. Clin. Diabetes 2015, 33 (2), 84–86.
25. Han, B.; Zhai, H.; Yu, J.; Xia, F.; Lu, Y. Diabetes Mellitus Associated with Pancreatic So-matostatin Tumor: A Case Report. J. Clin. Transl. Endocrinol. Case Reports 2016, 2, 20–22.
26. Shaikh, S. T.; Jadhav, S. S.; Shivane, V. K.; Lila, A. R.; Bandgar, T. R.; Shah, N. S. Childhood Onset of Sulfonylurea Responsive Neonatal Diabetes Due to a Novel Homozygous Autosomal Recessive Mutation in the ABCC8 Gene Which Was Presumed to Be Type 1B Diabetes Before Genetic Analysis. AACE Clin. Case Reports 2016, 2 (2), e117–e121.
27. Faundez, T.; Klee, P.; Hanquinet, S.; Schwitzgebel, V.; Burkhard, P. R.; Korff, C. M. Diabetic Striatopathy in Childhood: A Case Report. Pediatrics 2016, 137 (4).
28. Arce, K. M.and Pantalone, K. M. Not All Diabetes in Infants Is Type 1: A Case Report. Diabetes Ther. 2016, 7 (2), 369–375.
29. Saleh, A. Diagnosis of Type 1 Diabetes Mellitus in Adulthood – a Case Report. 2015, 44 (4), 233–235.
30. Kumar, R. S.; Singhi, P. K.and Kakkandki, K. Case Report of Two Cases of Patella Subacute Osteomyelitis in Diabetic Women A Rare Entity. J. Orthop. Case Reports 2016, 6 (2), 13–15.
31. Prasad, K. T.; Sehgal, I. S.; Shivaprakash, M. R.; Dhooria, S. Uncommon Mycosis in a Patient with Diabetes. BMJ Case Rep. 2016, bcr2016214453.
32. Saul, S. R.; Aleksic, S.and Magnotti, M. A Patient with Newly Diagnosed Diabetes Presenting with Sino-Orbital Mucormycosis. AACE Clin. Case Reports 2016, 2 (1), e41–e45.
33. Standards of Medical Care in Diabetes - 2016. Diabetes Care 2016, 39 (1), S1–S112.
34. Perkins, B. A.; Cherney, D. Z. I.; Partridge, H.; Soleymanlou, N.; Tschirhart, H.; Zinman, B.; Fagan, N. M.; Kaspers, S.; Woerle, H.-J.; Broedl, U. C.; Johansen, O.-E. Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial. Diabetes Care 2014, 37 (5), 1480–1483.
35. Liu, W.and Yang, X.-J. The Effect of Metformin on Adolescents with Type 1 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Int. J. Endocrinol. 2016, 2016, 1–12.
36. Inzucchi, S. E.; Bergenstal, R. M.; Buse, J. B.; Diamant, M.; Ferrannini, E.; Nauck, M.; Peters, A. L.; Tsapas, A.; Wender, R.; Matthews, D. R.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35 (6), 1364–1379.
37. Maruthur, N. M.; Tseng, E.; Hutfless, S.; Wilson, L. M.; Suarez-Cuervo, C.; Berger, Z.; Chu, Y.; Iyoha, E.; Segal, J. B.; Bolen, S. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes. Ann. Intern. Med. 2016, 164 (11), 1–20.
38. El-Kaissi, S.and Sherbeeni, S. Pharmacological Management of Type 2 Diabetes Mellitus: An Update. Curr. Diabetes Rev. 2011, 7 (6), 392–405.
39. Roy, H.; Brahma, C. K.; Nandi, S.; Parida, K. R. Formulation and Design of Sustained Release Matrix Tablets of Metformin Hydrochloride: Influence of Hypromellose and Polyacrylate Polymers. Int. J. Appl. basic Med. Res. 2013, 3 (1), 55–63.
40. Nanjwade, B. K.; Mhase, S. R.and Manvi, F. V. Formulation of Extended-Release Metformin Hydrochloride Matrix Tablets. Trop. J. Pharm. Res. 2011, 10 (4), 375–383.
41. Patil, S. A.; Kuchekar, B. S.; Chabukswar, A. R.; Jagdale, S. C. Formulation Evaluation of Extended-Release Solid Dispersion of Metformin Hydrochloride. J. Young Pharm. 2010, 2 (2), 121–129.
42. Jagdale, S.; Patil, S.; Kuchekar, B.; Chabukswar, A. Preparation and Characterization of Metformin Hydrochloride − Compritol 888 ATO Solid Dispersion. J. Young Pharm. 2011, 3 (3), 197–204.
43. Parveen, R.; Singh, A. P.; Kumar Bhargav, R.; Verma, A.; Priyanka, S. Formulation and evaluation of floating tablet of Metformin HCL. World J. Pharm. Pharm. Sci. 2016, 5 (7), 1317–1326.
44. Kumar, C. S.; Raja, M. D.; Sundar, D. S.; Gover Antoniraj, M.; Ruckmani, K. Hyaluronic Acid Co-Functionalized Gold Nanoparticle Complex for the Targeted Delivery of Metformin in the Treatment of Liver Cancer (HepG2 Cells). Carbohydr. Polym. 2015, 128, 63–74.
45. Seino, S. Cell Signalling in Insulin Secretion: The Molecular Targets of ATP, cAMP and Sulfonylurea. Diabetologia 2012, 55 (8), 2096–2108.
46. Davidson, J. Clinical Diabetes Mellitus: A Problem-Oriented Approach Diabetes Mellitus; Thieme Medical Publishers, 2000.
47. Mudgal, S.and Pancholi, S. Formulation of Glibenclamide Solid Dispersions by Solvent Evaporation Technique. J. Chem. Pharm. Res. 2012, 4 (1), 353–359.
48. Ning, X.; Sun, J.; Han, X.; Wu, Y.; Yan, Z.; Han, J.; He, Z. Strategies to Improve Dissolution and Oral Absorption of Glimepiride Tablets: Solid Dispersion versus Micronization Techniques. Drug Dev. Ind. Pharm. 2011, 37 (6), 727–736.
49. Mehsud, S. U.; Khan, G. M.; Hussain, A.; Akram, M.; Akhlaq, M.; Khan, K. A.; Shakoor, A. Controlled Release Matrix Tablets of Glipizide: Influence of Different Grades of Ethocel and Co-Excipient on Drug Release. Pak. J. Pharm. Sci. 2016, 29 (3), 779–787.
50. Maboos, M.; Yousuf, R. I.and Shoaib, M. H. Formulation Development and Optimization: Encapsulated System of Atenolol and Glyburide. Pak. J. Pharm. Sci. 2016, 29 (2), 569–577.
51. Meka, V. S.; Pillai, S.; Dharmalingham, S. R.; Sheshala, R.; Gorajana, A. Preparation and in Vitro Characterization of a Non-Effervescent Floating Drug Delivery System for Poorly Soluble Drug, Glipizide. Acta Pol. Pharm. 2015, 72 (1), 193–204.
52. Albertini, B.; Sabatino, M. Di; Melegari, C.; Passerini, N. Formulation of Spray Congealed Microparticles with Self-Emulsifying Ability for Enhanced Glibenclamide Dissolution Performance. J. Microencapsul. 2015, 32 (2), 181–192.
53. Mooranian, A.; Negrulj, R.; Al-Sallami, H. S.; Fang, Z.; Mikov, M.; Golocorbin-Kon, S.; Fak-houry, M.; Arfuso, F.; Al-Salami, H. Release and Swelling Studies of an Innovative Antidiabetic-Bile Acid Microencapsulated Formulation, as a Novel Targeted Therapy for Diabetes Treatment. J. Microencapsul. 2015, 32 (2), 151–156.
54. Blicklé, J. F. Meglitinide Analogues: A Review of Clinical Data Focused on Recent Trials. Diabetes Metab. 2006, 32 (2), 113–120.
55. Tavakoli, N.; Minaiyan, M.; Tabbakhian, M.; Pendar, Y. Preparation and Evaluation of a Controlled Drug Release of Repaglinide through Matrix Pellets: In Vitro and in Vivo Studies. J. Microencapsul. 2014, 31 (6), 529–534.
56. Akhtar, J.; Siddiqui, H. H.; Fareed, S.; Badruddeen; Khalid, M.; Aqil, M. Nanoemulsion: For Improved Oral Delivery of Repaglinide. Drug Deliv. 2016, 23 (6), 2026–2034.
57. Sharma, M.; Kohli, S.and Dinda, A. In-Vitro and in-Vivo Evaluation of Repaglinide Loaded Floating Microspheres Prepared from Different Viscosity Grades of HPMC Polymer. Saudi Pharm. J. 2015, 23 (6), 675–682.
58. Ebrahimi, H. A.; Javadzadeh, Y.; Hamidi, M.; Jalali, M. B. Repaglinide-Loaded Solid Lipid Nanoparticles: Effect of Using Different Surfactants/stabilizers on Physicochemical Properties of Nanoparticles. DARU J. Pharm. Sci. 2015, 23 (1), 46.
59. Gadadare, R.; Mandpe, L.and Pokharkar, V. Ultra Rapidly Dissolving Repaglinide Nano-sized Crystals Prepared via Bottom-Up and Top-Down Approach: Influence of Food on Phar-macokinetics Behavior. AAPS PharmSciTech 2015, 16 (4), 787–799.
60. Hauner, H. The Mode of Action of Thiazolidinediones. Diabetes. Metab. Res. Rev.18 Suppl 2, 2002, S10-5.
61. Sanrame, C. N.; Remenar, J. F.; Blumberg, L. C.; Waters, J.; Dean, R. L.; Dong, N.; Kriksciu-kaite, K.; Cao, P.; Almarsson, Ö. Prodrugs of Pioglitazone for Extended-Release (XR) Injectable Formulations. Mol. Pharm. 2014, 11 (10), 3617–3623.
62. Taupitz, T.; Dressman, J. B.and Klein, S. New Formulation Approaches to Improve Solubility and Drug Release from Fixed Dose Combinations: Case Examples Pioglitazone/glimepiride and Ezetimibe/simvastatin. Eur. J. Pharm. Biopharm. 2013, 84 (1), 208–218.
63. Zhang, H.; Qadeer, A.; Mynarcik, D.; Chen, W. Delivery of Rosiglitazone from an Injectable Triple Interpenetrating Network Hydrogel Composed of Naturally Derived Materials. Bioma-terials 2011, 32 (3), 890–898.
64. Mohan Kamila, M.; Mondal, N.; Kanta Ghosh, L.; Kumar Gupta, B. Multiunit Floating Drug Delivery System of Rosiglitazone Maleate: Development, Characterization, Statistical Optimization of Drug Release and In Vivo Evaluation. AAPS PharmSciTech 2009, 10 (3), 887–899.
65. Dej-Adisai, S.and Pitakbut, T. Determination of a-Glucosidase Inhibitory Activity from Selected Fabaceae Plants. Pak. J. Pharm. Sci. 2015, 28 (5), 1679–1683.
66. Zhao, H.; Zhang, Y.; Guo, Y.; Shi, S. Identification of Major α-Glucosidase Inhibitors in Ra-dix Astragali and Its Human Microsomal Metabolites Using Ultrafiltration HPLC–DAD–MSn. J. Pharm. Biomed. Anal. 2015, 104, 31–37.
67. Uddin, G.; Rauf, A.; Al-Othman, A. M.; Collina, S.; Arfan, M.; Ali, G.; Khan, I. Pistagremic Acid, a Glucosidase Inhibitor from Pistacia Integerrima. Fitoterapia 2012, 83 (8), 1648–1652.
68. Haas, B.; Eckstein, N.; Pfeifer, V.; Mayer, P.; Hass, M. D. S. Efficacy, Safety and Regulatory Status of SGLT2 Inhibitors: Focus on Canagliflozin. Nutr. Diabetes 2014, 4, e143.
69. Powell, J.; Miller, S. A.and Taylor, J. R. Sodium-Glucose Cotransporter 2 Inhibitors: The New Option for Diabetes Mellitus Management. South. Med. J. 2015, 108 (2), 82–90.
70. Wu, J. H. Y.; Foote, C.; Blomster, J.; Toyama, T.; Perkovic, V.; Sundström, J.and Neal, B. Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiovascular Events, Death, and Major Safety Outcomes in Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Lancet Diabetes Endocrinol. 2016, 4 (5), 411–419.
71. Brunton, S. GLP-1 Receptor Agonists vs. DPP-4 Inhibitors for Type 2 Diabetes: Is One Approach More Successful or Preferable than the Other? Int. J. Clin. Pract. 2014, 68 (5), 557–567.
72. Behme, M. T.; Dupré, J.and McDonald, T. J. Glucagon-like Peptide 1 Improved Glycemic Control in Type 1 Diabetes. BMC Endocr. Disord. 2003, 3 (1), 3.
73. Koliaki, C.and Doupis, J. Incretin-Based Therapy: A Powerful and Promising Weapon in the Treatment of Type 2 Diabetes Mellitus. Diabetes Ther. 2011, 2 (2), 101–121.
74. Chen, M.; Liu, Y.; Jin, J.and He, Q. The Efficacy and Safety of Dipeptidyl Peptidase-4 In- hibitors for Treatment of Type 2 Diabetes Mellitus Patients with Severe Renal Impairment: A Meta-Analysis. Ren. Fail. 2016, 38 (4), 581–587.
75. Karagiannis, T.; Boura, P.and Tsapas, A. Safety of Dipeptidyl Peptidase 4 Inhibitors: A Perspective Review. Ther. Adv. Drug Saf. 2014, 5 (3), 138–146.
76. Trujillo, J. M.; Nuffer, W.and Ellis, S. L. GLP-1 Receptor Agonists: A Review of Head-to-Head Clinical Studies. Ther. Adv. Endocrinol. Metab. 2015, 6 (1), 19–28.
77. Kalra, S.; Baruah, M.; Sahay, R.; Unnikrishnan, A.; Uppal, S.; Adetunji, O. Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Type 2 Diabetes: Past, Present, and Future. Indian J. Endocrinol. Metab. 2016, 20 (2), 254.
78. Prasad-Reddy, L. and Isaacs, D. A Clinical Review of GLP-1 Receptor Agonists: Efficacy and Safety in Diabetes and beyond. Drugs Context 2015, 4, 1–19.
79. Sharma, G.; Sharma, A. R.; Nam, J.-S.; Doss, G. P. C.; Lee, S.-S.; Chakraborty, C. Nanoparticle Based Insulin Delivery System: The next Generation Efficient Therapy for Type 1 Diabetes. J. Nanobiotechnology 2015, 13 (1), 74.
80. Alai, M. S.; Lin, W. J.and Pingale, S. S. Application of Polymeric Nanoparticles and Micelles in Insulin Oral Delivery. J. Food Drug Anal. 2015, 23 (3), 351–358.
81. Subramani, K. and Pathak, S. Recent Trends in Diabetes Treatment Using Nanotechnology. 2012, 7 (1), 85–95.
82. Ezuruike, U. F. and Prieto, J. M. The Use of Plants in the Traditional Management of Diabetes in Nigeria: Pharmacological and Toxicological Considerations. J. Ethnopharmacol. 2014, 155 (2), 857–924.
83. Patel, D. K.; Kumar, R.; Laloo, D.; Hemalatha, S. Diabetes Mellitus: An Overview on Its Pharmacological Aspects and Reported Medicinal Plants Having Antidiabetic Activity. Asian Pac. J. Trop. Biomed. 2012, 2 (5), 411–420.
84. Rahimi, M. A Review: Anti Diabetic Medicinal Plants Used for Diabetes Mellitus. Bull. Environ. Pharmacol. Life Scienes 2015, 4 (2), 163–180.